[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"polyvascular-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:polyvascular-disease":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,47,69],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100533910","randomized-comparison-of-efficacy-and-safety-of-high-intensity-rosuvastatinezetimibe-combination-versus-treat-to-target-rosuvastatin-monotherapy-for-patients-with-peripheral-artery-or-polyvascular-disease-care-pvd-trial-100533910",false,"NCT06231966","Randomized Comparison of Efficacy and Safety of High-intensity Rosuvastatin\u002FEzetimibe Combination Versus Treat-to-target Rosuvastatin Monotherapy for Patients With Peripheral Artery or Polyvascular Disease (CARE-PVD Trial)","Inclusion criteria:\n\n1. Ages 19-80\n2. Patient with arteriosclerotic lower extremity artery disease or multivessel disease 1) Arteriosclerotic lower extremity artery disease: If any of the following applies\n\n   * Ankle-brachial index \\\u003C0.85 with symptoms of intermittent claudication\n   * Lower extremity artery stenosis of more than 50% on imaging tests\n   * History of receiving interventional or surgical treatment for lower extremity artery disease) 2) Arteriosclerotic multivessel disease: When at least two of the following diseases exist even if there is no lower extremity artery disease\n   * Coronary artery disease\n   * History of carotid artery stenosis (more than 50%) or ischemic stroke\u002Ftransient cerebral ischemia event\n   * degenerative thoracic (maximum diameter \\>4 cm) or abdominal (maximum diameter \\>3cm) aortic aneurysm\n3. Patients on medication for dyslipidemia or patients with LDL cholesterol level higher than the target level for peripheral arterial disease (≥70 mg\u002FdL) and not on lipid lowering medication\n\nExclusion criteria:\n\n1. Chronic limb threatening ischemia (Rutherford 4\\~6)\n2. History of acute coronary syndrome or stroke\u002FTIA or lower extremity amputation within 6 months\n3. Acute liver disease or persistent unexplained elevation of serum AST or ALT more than twice the upper limit of normal\n4. Severe renal dysfunction (eGFR \\\u003C30 mL\u002Fmin\u002F1.73m2) or dependancy on dialysis\n5. History of allergic or hypersensitivity reaction to statin or ezetimibe or side effects requiring discontinuation of lipid lowering therapy\n6. Solid organ transplant recipients\n7. Pregnant women, potentially pregnant or lactating women\n8. Life expectancy of less than 3 years\n9. When follow-up for more than 1 year is not possible\n10. Inability to understand or read the consent form","ALL","19 Years","80 Years",{"count":19,"type":20},2462,"ESTIMATED","INTERVENTIONAL",[23],"NA","Patients with atherosclerotic peripheral artery disease often have combined coronary artery disease or cerebral artery disease and show high rates of cardiovascular mortality and morbidities. Therefore, secondary prevention for these patients is of great clinical importance. Currently, Korean, US, and European guidelines recommend different LDL cholesterol target goals in patients with peripheral artery disease. In recent clinical trials, combination therapy of statin plus ezetimibe demonstrated improved cardiovascular outcomes compared with statin monotherapy. Thus, the purpose of the CARE-PVD study is to investigate whether the combination therapy of high intensity rosuvastatin 20 mg plus ezetimibe 10 mg can improve cardiovascular outcomes in patient with peripheral artery disease or polyvascular artery disease in comparison with rosuvastatin treat-to-target (LDL cholesterol \\\u003C70 mg\u002FdL) monotherapy.",[26,27],"Peripheral Artery Disease","Polyvascular Disease",[29,30,31,32,33],"Peripheral artery disease","polyvascular disease","lipid lowering therapy","LDL cholesterol","Clinical outcomes","RECRUITING","2025-05-14",{"date":37,"type":38},"2025-05-20","ACTUAL",{"date":40,"type":38},"2024-04-22",{"date":42,"type":20},"2029-05-06",{"name":44,"class":45},"Yonsei University","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":15,"minAge":54,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":46},"100517366","an-imaging-study-of-polyvascular-disease-100517366","NCT06016608","An Imaging Study of Polyvascular Disease","Early Screen, Systematic Evaluation and Risk Warning of Polyvascular Disease Based on Multi-modality Imaging","Inclusion Criteria:\n\nTask 1:\n\n1. Patients with coronary artery disease (≥50% stenosis in any coronary artery on coronary angiography)\n2. Age ≥18 years old\n3. Proposed OCT-IVUS integrated imaging system\n4. able to provide written informed consent prior to the start of any procedures related to the study.\n\nTask 2:\n\n1. patients with coronary artery disease (coronary angiography reveals ≥50% degree of stenosis in any coronary artery) and patients with stroke or TIA (confirmed by a neurologist)\n2. Age ≥ 18 years\n3. able to provide written informed consent prior to the start of any procedures related to the study.\n\nExclusion Criteria:\n\nTask 1:\n\n1. severely tortuous\u002Fcalcified coronary arteries with anticipated difficulty in completing the OCT-IVUS integrated imaging system\n2. uncontrolled congestive heart failure or acute left heart failure;plan\n3. claustrophobia;\n4. left main stem occlusion;\n5. proposed coronary artery bypass grafting (CABG);\n6. uncontrolled severe ventricular arrhythmia;\n7. active bleeding or severe bleeding tendency;\n8. acute stroke;\n9. patients with hemodynamic instability or unstable cardiac electrical activity (including shock) ;\n10. severe renal insufficiency and\u002For anuria, except in cases where dialysis treatment has been planned;\n11. contraindications to the application of contrast media;\n12. patients who are severely uncooperative due to psychiatric or serious systemic illness;\n13. Patients who, in the opinion of the investigator, are unsuitable for participation in the study.\n\nTask 2:\n\n1. patients who are unable to comply with the follow-up schedule;\n2. uncontrolled congestive heart failure or acute left heart failure;\n3. patients with a life expectancy of less than 6 months;\n4. left main stem occlusion;\n5. proposed coronary artery bypass grafting (CABG);\n6. uncontrolled severe ventricular arrhythmia;\n7. active bleeding or severe bleeding tendency;\n8. patients with hemodynamic instability or unstable cardiac electrical activity (including shock) ;\n9. severe renal insufficiency and\u002For anuria, except in cases where dialysis treatment has been planned;\n10. contraindications to the application of contrast media;\n11. patients who are severely uncooperative due to psychiatric or serious systemic illness;\n12. patients who, in the opinion of the investigator, are not suitable for participation in the study.","18 Years",{"count":56,"type":20},1100,"OBSERVATIONAL","1. Establish a multimodality imaging database for PVD, improve the one-stop screening process for early PVD based on artificial intelligence, build a full-cycle control information platform, and promote the construction and standardization of a multidisciplinary co-morbidity and co-management diagnosis and treatment model.\n2. Based on non-invasive, zero-contrast ocular OCTA combined with one-stop CTA imaging of the heart and brain, construct an integrated \"eye-heart-brain\" early warning model for PVD, and explore a potential non-invasive and convenient early warning system for PVD.\n3. Based on the multi-omics, investigate EVs-mediated intercellular communication network, elucidate the roles and regulatory mechanisms of EVs in the development of PVD, search for potential targets for intervention, and construct an artificial intelligence-based \"pan-vascular score\" risk assessment system based on the combination of multi-modality imaging and multi-omics biomarkers.",[27],"2024-12-22",{"date":62,"type":38},"2024-12-27",{"date":64,"type":38},"2023-10-18",{"date":66,"type":20},"2025-12-31",{"name":68,"class":45},"Harbin Medical University",{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":15,"minAge":77,"maxAge":4,"enrollmentInfo":78,"targetDuration":4,"studyType":21,"phases":80,"briefSummary":81,"conditions":82,"keywords":83,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":95,"locationsCount":4},"100567277","effects-of-n3-lc-pufas-on-inflammatory-immune-and-senescence-features-in-polyvascular-older-subjects-omsage-100567277","NCT06666101","Effects of n3 LC PUFAs on Inflammatory, Immune and Senescence Features in Polyvascular Older Subjects (OMSAGE)","Immunomodulatory Effects of Polyunsaturated ω-3 Fatty Acids in Old Patients With Polyvascular Disease: a Double-blind, Randomized, Controlled, Factorial 2x2 Trial (\"OMEGA3\" Study)","OMSAGE","Inclusion Criteria:\n\n* ≥ 75 years old\n* Patients with polyvascular disease in cases of vascular lesions in ≥2 disease territories or any combination of coronary, peripheral, or carotid artery disease.\n* Able to comply with the requirements of the study protocol\n* Signed informed consent form approved by the ethical committee\n* No illness or event within 2 months prior to inclusion (hospitalization, trauma, active cancer, infection, acute failure of chronic disease, surgical intervention)\n* No history of multiple and\u002For severe allergies to drugs or foods\n* No consumption of fish oil or omega-3 fatty acid supplements within 2 months prior to inclusion\n* No consumption of more than 500 mg\u002Fday of dietary omega-3 fatty acids (questionnaire)\n* No intake of anti-inflammatory or corticosteroid medication within 2 weeks prior to inclusion\n* Able and authorized to take a pill\n* No intervention planned in the months following the start of the study\n\nExclusion Criteria:\n\n* Inflammatory syndrome (CRP \\>10 mg\u002Fl) on day 0 and day 7\n* Acute illness or event during the time of intervention","75 Years",{"count":79,"type":20},80,[23],"The objectives is to evaluate the effect of omega-3 fatty acids in old participants with polyvascular disease on immune parameters and inflammatory mediators at different times. Three modalities of administration of omega-3 will be compared with a placebo (olive oil): predominant EPA (Eicosapentaenoic acid), predominant DHA (doxosahexaenoic acid), and combinaison of both. This study will measure the level of omega3 fatty acids in this population 4 hours after taking, on the 7th day, on the 21th day of administration and 1 month after administration.",[27],[84,85,86,87],"fatty acid, omega 3","immune response","inflammatory mediators","macrophage polarisation","NOT_YET_RECRUITING","2024-10-28",{"date":91,"type":38},"2024-10-30",{"date":93,"type":20},"2024-11-04",{"date":66,"type":20},{"name":96,"class":45},"Université Libre de Bruxelles"]